HPV vaccine shows success in gay, bisexual men

A study by Monash University and Alfred Health found a 70 per cent reduction in one type of human papillomavirus (HPV) in gay and bisexual men after the implementation of the school-based HPV vaccination program.

The HYPER2 study, published in Lancet Infectious Diseases, and led by Associate Professor Eric Chow, found there was a significant reduction in all four vaccine-preventable genotypes in gay/bisexual men aged 16-20 years following the introduction of the vaccine for boys in 2013.

Significant drop in genital warts in young people thanks to national HPV vaccination program

Human papillomavirus (HPV) under the microscope

Text adapted courtesy Alfred Health

New research data show cases of genital warts in young Australians have dropped 90 per cent in the last decade.

Dr Eric Chow from the Melbourne Sexual Health Centre, who presented the data at the 32nd International Papillomavirus Conference in Sydney and is currently presenting a poster of the research in New Zealand at the 2018 IUSTI Asia Pacific Sexual Health Congress, said the reduction is thanks to Australia's highly successful National HPV (Human Papillomavirus) Vaccination Program. 

Participants sought: Does vaccinating males against HPV help to reduce HPV in males?

Vaccinating men for HPV - will it help reduce HPV?

Prevalence of genital HPV infection in males following introduction of universal male Human Papillomavirus (HPV) vaccination - IMPRESS

                          

This study will find out how common HPV is among males aged 17 to 19 years. We will compare two groups: males who have been offered vaccination against HPV as part of the vaccination program and those who were not offered the vaccination.

Female HPV vaccination programmes are effective in reducing infections

Prof Christopher Fairley, Director of Melbourne Sexual Health
Centre, and colleagues. Prof Fairley is an author on this paper.

Human papillomavirus (HPV) vaccination programmes were first implemented in several countries worldwide in 2007. We did a systematic review and meta-analysis to assess the population-level consequences and herd effects after female HPV vaccination programmes, to verify whether or not the high efficacy reported in randomised controlled clinical trials are materialising in real-world situations.